unknown
Stage
About
Virion Therapeutics is a clinical-stage biopharmaceutical company developing T cell-based immunotherapies that use proprietary checkpoint modifiers to restore, enhance, broaden, and elicit sustained CD8+ T cell responses against cancer and chronic infectious diseases. Its lead program, VRON-0200 for chronic hepatitis B virus (HBV), completed a Phase 1b trial showing durable anti-HBV activity following a single, well-tolerated dose.
Explore Virion Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.